Zacks Research Issues Pessimistic Outlook for BIO Earnings

Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) - Investment analysts at Zacks Research decreased their Q2 2025 earnings per share (EPS) estimates for shares of Bio-Rad Laboratories in a research report issued on Thursday, July 10th. Zacks Research analyst R. Department now anticipates that the medical research company will post earnings of $1.93 per share for the quarter, down from their prior forecast of $2.03. The consensus estimate for Bio-Rad Laboratories' current full-year earnings is $10.81 per share. Zacks Research also issued estimates for Bio-Rad Laboratories' Q4 2025 earnings at $2.57 EPS, FY2025 earnings at $9.23 EPS, Q1 2026 earnings at $2.79 EPS, Q3 2026 earnings at $2.49 EPS, Q4 2026 earnings at $2.78 EPS, FY2026 earnings at $10.52 EPS and Q1 2027 earnings at $2.45 EPS.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The medical research company reported $2.54 EPS for the quarter, topping analysts' consensus estimates of $1.73 by $0.81. The business had revenue of $585.40 million for the quarter, compared to analysts' expectations of $573.01 million. Bio-Rad Laboratories had a positive return on equity of 4.32% and a negative net margin of 85.16%. The business's quarterly revenue was down 4.2% on a year-over-year basis. During the same period in the previous year, the firm earned $2.30 EPS.

Other equities research analysts have also issued reports about the company. Royal Bank Of Canada cut their price objective on Bio-Rad Laboratories from $409.00 to $392.00 and set an "outperform" rating on the stock in a research report on Friday, May 2nd. UBS Group cut their price objective on Bio-Rad Laboratories from $355.00 to $310.00 and set a "buy" rating on the stock in a research report on Friday, May 2nd. Citigroup cut their price objective on Bio-Rad Laboratories from $400.00 to $350.00 and set a "buy" rating on the stock in a research report on Friday, May 2nd. Wells Fargo & Company cut their price objective on Bio-Rad Laboratories from $260.00 to $245.00 and set an "equal weight" rating on the stock in a research report on Monday, June 9th. Finally, Wall Street Zen lowered Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a research report on Sunday. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat, Bio-Rad Laboratories currently has an average rating of "Moderate Buy" and an average target price of $324.25.

Bio-Rad Laboratories Trading Down 2.4%

Shares of BIO stock traded down $6.05 during trading hours on Friday, reaching $250.92. The company's stock had a trading volume of 246,517 shares, compared to its average volume of 335,990. The stock has a market capitalization of $6.83 billion, a P/E ratio of -3.29 and a beta of 0.95. Bio-Rad Laboratories has a one year low of $211.43 and a one year high of $387.99. The firm's fifty day simple moving average is $237.15 and its 200 day simple moving average is $268.72. The company has a current ratio of 5.99, a quick ratio of 4.43 and a debt-to-equity ratio of 0.18.

Institutional Investors Weigh In On Bio-Rad Laboratories

Hedge funds have recently made changes to their positions in the company. GAMMA Investing LLC boosted its holdings in Bio-Rad Laboratories by 20.9% in the second quarter. GAMMA Investing LLC now owns 734 shares of the medical research company's stock worth $177,000 after acquiring an additional 127 shares in the last quarter. UMB Bank n.a. boosted its holdings in Bio-Rad Laboratories by 89.8% in the second quarter. UMB Bank n.a. now owns 167 shares of the medical research company's stock worth $40,000 after acquiring an additional 79 shares in the last quarter. Exchange Traded Concepts LLC boosted its holdings in Bio-Rad Laboratories by 123.4% in the second quarter. Exchange Traded Concepts LLC now owns 13,932 shares of the medical research company's stock worth $3,362,000 after acquiring an additional 7,697 shares in the last quarter. Wealth Enhancement Advisory Services LLC bought a new stake in Bio-Rad Laboratories in the second quarter worth $238,000. Finally, Harbor Capital Advisors Inc. boosted its holdings in Bio-Rad Laboratories by 2.0% in the second quarter. Harbor Capital Advisors Inc. now owns 9,254 shares of the medical research company's stock worth $2,233,000 after acquiring an additional 183 shares in the last quarter. 65.24% of the stock is currently owned by institutional investors.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.